Manipulating the infant respiratory microbiomes to improve clinical outcomes: A review of the literature - 12/05/21
, Robert B Dorey a, Jay R Laver a, David W Cleary a, Robert C Read a, b, Christine E Jones b, cHighlights |
• | Infant respiratory microbiome profiles are associated with disease (including respiratory tract infections and asthma), although the mechanism for this remains unclear. |
• | There have been increasing attempts since the 1960s to alter infant respiratory pathogen carriage and clinical outcomes using live bacteria and their substrates. |
• | However, the evidence for these interventions is heterogeneous, and there is insufficient high-quality evidence to recommend their widespread use. |
• | Controlled human challenge studies offer an avenue for characterising the clinical, immunological and microbiome effects of such live bacterial interventions in infants. |
Summary |
Background |
The association between infant respiratory microbiota and disease (including respiratory tract infections and asthma) is increasingly recognised, although the mechanism remains unclear. Respiratory infections and asthma account for a large proportion of infant morbidity and mortality, so the possibility of preventing disease or modifying clinical outcomes by manipulating microbiome development warrants investigation.
Objectives and methods |
We identified studies that investigated the efficacy of live bacteria (probiotics or human challenge) or their substrates to modify respiratory colonisation or clinical outcomes in infants.
Eligibility criteria |
Interventional studies involving infants under one year of age, administration of live bacteria or their substrates, and outcome measures including bacterial colonisation, microbiome profile, or respiratory disease phenotypes.
Results and limitations |
Some bacterial interventions can reduce infant respiratory infections, although none have been shown to reduce asthma incidence. The literature is heterogeneous in design and quality, precluding meaningful meta-analysis.
Conclusions |
Upper respiratory tract infant microbiome manipulation may alter outcomes in respiratory tract infection, but further well-conducted research is needed to confirm this. Improved regulation of proprietary bacterial products is essential for further progress.
Le texte complet de cet article est disponible en PDF.Keywords : Probiotic, Microbiome, Human challenge, Respiratory, Infant
Plan
Vol 82 - N° 6
P. 247-252 - juin 2021 Retour au numéro
Article précédent
- Epidemiology and clinical outcomes of severe Plasmodium vivax malaria in India
- Loick P. Kojom Foko, Aditi Arya, Amit Sharma, Vineeta Singh
- Exhaled SARS-CoV-2 quantified by face-mask sampling in hospitalised patients with COVID-19
- Caroline M. Williams, Daniel Pan, Jonathan Decker, Anika Wisniewska, Eve Fletcher, Shirley Sze, Sara Assadi, Richard Haigh, Mohamad Abdulwhhab, Paul Bird, Christopher W Holmes, Alaa Al-Taie, Baber Saleem, Jingzhe Pan, Natalie J Garton, Manish Pareek, Michael R Barer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?